Dr. Julie Bergeron is an Associate Professor of Medicine at the University of Montreal. She works in the Hematology Division at CEMTL, Hôpital Maisonneuve-Rosemont and Institut universitaire d’Hémato-Oncologie et Thérapie cellulaire (IHOT).

After her training in hematology she completed a post doctoral fellowship in Paris at Necker-Enfants-Malades in Molecular Biology of Hematologic Malignancies. Her clinical practice is focused on Acute Leukemias, both lymphoblastic and myeloblastic. She has acted as the site or national PI in multiple clinical trials in the field of Acute Leukemias. She also has a laboratory practice in the Molecular Diagnosis Laboratory and is head of the Hematology Laboratory Service of OPTILAB CHUM. 

Dr. Gwynivere Davies practices malignant hematology at the Juravinski Hospital and Cancer Centre in Hamilton, Ontario, with a clinical focus on lymphoma and CLL, autologous stem cell transplantation and CAR-T. She is an Associate Professor of Oncology at McMaster University and serves as Division Head of Malignant Hematology and Director of the Lymphoma Fellowship program. Her research centers on the introduction of novel agents in frontline and relapsed/refractory lymphoma, the impact of social determinants of health on lymphoma outcomes, and health services research. Her peer-reviewed grant topics include ICES database research in indolent non-Hodgkin lymphoma and CAR-T knowledge translation, and she has led and co-authored numerous peer-reviewed studies on secondary malignancies and survival outcomes following lymphoma diagnosis and treatments, bispecific antibodies, CAR-T outcomes and toxicities and hematology residency education innovations, maintaining an active publication and presentation record at national and international conferences.

Dr. Dawn Maze is a clinician investigator at the Princess Margaret Cancer Centre and an Assistant Professor in the Department of Medicine at the University of Toronto. She is a member of the Leukemia Site Group and the Myeloproliferative Neoplasms (MPN) Program and has a clinical research interest in myeloid malignancies. Her primary research focus is in MPN, particularly in risk stratification and management approaches early in the disease course and in the adolescent/young adult population. 

She is particularly interested in optimizing pregnancy outcomes in this population. She is also actively involved in clinical trials and projects aiming to refine risk stratification in acute myeloid leukemia. Dr. Maze is an active member of the Canadian MPN Group. She is the Medical Director for the Malignant Hematology Day Unit at Princess Margaret and the Program Director for the Leukemia Fellowship Program.

Dr. Robert Puckrin is a Hematologist and Clinician Investigator at the Arthur Child Cancer Centre and the University of Calgary in Calgary, Canada. His main interests are in lymphoma, stem cell transplantation and cellular therapies, bispecific antibodies, clinical trials, and real-world data.